Date | Product | Disease | Phase | Company | Therapeutic area |
---|---|---|---|---|---|
2013-08-27 | miravirsen | hepatitis C | 2 | Santaris Pharma (Denmark) | Infectious diseases |
2013-08-26 | IC84 | Clostridium difficile infections | 1 | Intercell (Austria) now Valvena | Infectious diseases |
2013-08-26 | Fluzone® High-Dose Vaccine | nfluenza | Sanofi Pasteur (France) | Infectious diseases | |
2013-08-23 | vercirnon (Traficet-EN, now designated GSK1605786 (‘786) | Crohn's disease | 3 | GSK (UK) ChemoCentryx (USA) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2013-08-21 | onapristone | PK | Arno Therapeutics (USA) | Cancer - Oncology | |
2013-08-20 | melflufen (melphalan-flufenamide) | multiple myeloma |
2 | Oncopeptides (Sweden) | Cancer - Oncology |
2013-08-19 | 2B3-101 (brain targeted doxorubicin liposomes) | patients with solid tumors and brain metastases or recurrent malignant glioma |
1-2 | to-BBB (The Netherlands) | Cancer - Oncology |
2013-08-07 | WX-037 | solid tumours | 1 | Wilex (Germany) | Cancer - Oncology |
2013-08-07 | GNX-5086 | myocardial infarction | 1 | Congenia (Italy) | Cardiovascular diseases |
2013-08-06 | olesoxime as a complementary therapy to MS treatment with interferon beta | multiple sclerosis | 1b | Trophos (France) | Autoimmune diseases – Neurodegenerative diseases |
2013-07-31 | linagliptin (Tradjenta® in the US and Trajenta® in Europe) | type 2 diabetes | Boehringer Ingelheim (Germany) Eli Lilly (USA) | Metabolic diseases - Cardiovascular diseases | |
2013-07-29 | glial cell line-derived neurotrophic factor (GDNF)-based gene therapy | Parkinson\'s disease | 1 | Uniqure (The Netherlands) University of California, San Francisco (UCSF) (USA) | Neurodegenerative diseases - CNS diseases |
2013-07-26 | Adoptive cellular therapy | pre-emptive treatment of cytomegalovirus (CMV) infections in patients who have received a bone marrow transplant from an unrelated donor |
2 | Cell Medica (UK) | Infectious diseases - Transplantation |
2013-07-25 | resminostat | non-small-cell lung cancer (NSCLC) | 1-2 | Yakult Honsha (Japan) 4SC (Germany) | Cancer - Oncology |
2013-07-24 | riociguat | pulmonary arterial hypertension (PAH) |
3 | Bayer (Germany) | Rare diseases - Cardiovascular diseases |
2013-07-24 | riociguat | chronic thromboembolic pulmonary hypertension (CTEPH) |
3 | Bayer (Germany) | Cardiovascular diseases |
2013-07-17 | ELND005 | agitation/aggression in patients with moderate to severe Alzheimer’s disease | 2 | Elan (Ireland) | Neurodegenerative diseases |
2013-07-17 | Alpharadin®/Xofigo® (radium-223 dichloride) | castration-resistant prostate cancer with bone metastases | 3 | Algeta (Norway) Bayer Healthcare (Germany) | Cancer - Oncology |
2013-07-09 | emibetuzumab (LY2875358) | non-small cell lung cancer (NSCLC) | 2 | Eli Lilly (USA - IN) | Cancer - Oncology |
2013-07-09 | Unyvero™ P50 pneumonia application | pneumonia | Curetis (Germany) | Infectious diseases |